Verastem is a late stage development biopharmaceutical company, with ongoing registration directed trials, focused on developing and commercializing medicines for patients battling cancer. Co.'s product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors. VS-6766 is an orally available small molecule rapidly accelerated fibrosarcoma/ mitogen-activated protein kinase kinase clamp. Defactinib is an oral small molecule inhibitor of Focal Adhesion Kinase and proline-rich tyrosine kinase that is being evaluated as a potential combination therapy for various solid tumors. We show 48 historical shares outstanding datapoints in our VSTM shares outstanding history coverage, used to compute VSTM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VSTM market cap history over the course of time is important for investors
interested in comparing VSTM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VSTM versus a peer is one thing; comparing
VSTM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VSTM can fluctuate over the course of history.
With this page we aim to empower investors researching VSTM by allowing them to research the VSTM market cap history. |
Free VSTM Email Alerts:
Video: The Importance of Market Cap
